The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants
Open accessAbstract
Antibodies to transferrin receptor (TfR) have potential use for therapeutic entry into the brain. We have shown that bispecific antibodies against TfR and β-secretase (BACE1 [β-amyloid cleaving enzyme-1]) traverse the blood–brain barrier (BBB) and effectively reduce brain amyloid β levels. We found that optimizing anti-TfR affinity improves brain exposure and BACE1 inhibition. Here we probe the cellular basis of this improvement and explore whether TfR antibody affinity alters the intracellular trafficking of TfR. Comparing high- and low-affinity TfR bispecific antibodies in vivo, we found that high-affinity binding to TfR caused a dose-dependent reduction of brain TfR levels. In vitro live imaging and colocalization experiments revealed that high-affinity TfR bispecific antibodies facilitated the trafficking of TfR to lysosomes and thus induced the degradation of TfR, an observation which was further confirmed in vivo. Importantly, high-affinity anti-TfR dosing induced reductions in brain TfR levels, which significantly decreased brain exposure to a second dose of low-affinity anti-TfR bispecific. Thus, high-affinity anti-TfR alters TfR trafficking, which dramatically impacts the capacity for TfR to mediate BBB transcytosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
pH and the recycling of transferrin during receptor-mediated endocytosis.
Dautry-Varsat, A., Ciechanover, A., & Lodish, H. F. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.8.2258 · Cited by 1,179
Transferrin receptor on endothelium of brain capillaries
Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984) · Nature · doi:10.1038/312162a0 · Cited by 1,061
Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window
Holtmaat, A., Bonhoeffer, T., Chow, D. K., Chuckowree, J., De Paola, V., Hofer, S. B., Hübener, M., Keck, T., Knott, G., Lee, W.-C. A., et al. (2009) · Nature Protocols · doi:10.1038/nprot.2009.89 · Cited by 1,023
THE CELL BIOLOGY OF THE BLOOD-BRAIN BARRIER
Rubin, L. L., & Staddon, J. M. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.11 · Cited by 1,000
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Self-citationBlood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
Receptor‐mediated transcytosis of transferrin across the blood‐brain barrier
Fishman, J. B., Rubin, J. B., Handrahan, J. V., Connor, J. R., & Fine, R. E. (1987) · Journal of Neuroscience Research · doi:10.1002/jnr.490180206 · Cited by 544
Spatial control of EGF receptor activation by reversible dimerization on living cells
Chung, I., Akita, R., Vandlen, R., Toomre, D., Schlessinger, J., & Mellman, I. (2010) · Nature · doi:10.1038/nature08827 · Cited by 538
Self-citationA Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274
Self-citationAddressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., Solanoy, H., Tong, R. K., Hoyte, K., Luk, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005338 · Cited by 268
Self-citation
Cited by
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
“However, instead of crossing the BBB, the AuNPs conjugated with anti-TfR Abs were restricted in the endothelium cells independent of the acid-cleavable linkers, which had been previously demonstrated by their trafficking to lysosomes [132,133].”
BackgroundDilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
Andreone, B. J., Chow, B. W., Tata, A., Lacoste, B., Ben-Zvi, A., Bullock, K., Deik, A. A., Ginty, D. D., Clish, C. B., & Gu, C. (2017) · Neuron · doi:10.1016/j.neuron.2017.03.043 · Cited by 636
Development and Cell Biology of the Blood-Brain Barrier
Langen, U. H., Ayloo, S., & Gu, C. (2019) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062608 · Cited by 511
The role of interleukin-6 signaling in nervous tissue
Rothaug, M., Becker-Pauly, C., & Rose-John, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.018 · Cited by 491
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482
Drug delivery to the central nervous system
Nance, E., Pun, S. H., Saigal, R., & Sellers, D. L. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00394-w · Cited by 414
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Ferritin Nanocarrier Traverses the Blood Brain Barrier and Kills Glioma
Fan, K., Jia, X., Zhou, M., Wang, K., Conde, J., He, J., Tian, J., & Yan, X. (2018) · ACS Nano · doi:10.1021/acsnano.7b06969 · Cited by 395
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 370
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J. A., Meilandt, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009835 · Cited by 371
Self-citationGlucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 361
Agrawal, M., Ajazuddin, Tripathi, D. K., Saraf, S., Saraf, S., Antimisiaris, S. G., Mourtas, S., Hammarlund-Udenaes, M., & Alexander, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.019 · Cited by 356
Kariolis, M. S., Wells, R. C., Getz, J. A., Kwan, W., Mahon, C. S., Tong, R., Kim, D. J., Srivastava, A., Bedard, C., Henne, K. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1359 · Cited by 349
Self-citationTranscytosis at the blood–brain barrier
Ayloo, S., & Gu, C. (2019) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2018.12.014 · Cited by 296
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
“Using in vivo imaging, it was shown that high affinity ligands induced trafficking to lysosomes and degradation [103].”
BackgroundDiscovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies
Zuchero, Y. J. Y., Chen, X., Bien-Ly, N., Bumbaca, D., Tong, R. K., Gao, X., Zhang, S., Hoyte, K., Luk, W., Huntley, M. A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.024 · Cited by 282
Self-citationClark, A. J., & Davis, M. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517048112 · Cited by 280
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268
Drug Delivery to the Brain across the Blood–Brain Barrier Using Nanomaterials
Tsou, Y., Zhang, X., Zhu, H., Syed, S., & Xu, X. (2017) · Small · doi:10.1002/smll.201701921 · Cited by 258
Neuronal and vascular interactions
Andreone, B. J., Lacoste, B., & Gu, C. (2015) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071714-033835 · Cited by 256
Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: impact of genetic risk factors
Van Acker, Z. P., Bretou, M., & Annaert, W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0323-7 · Cited by 222
“currently focused on bifunctional antibodies directed against the transferrin receptor [157].”
Ullman, J. C., Arguello, A., Getz, J. A., Bhalla, A., Mahon, C. S., Wang, J., Giese, T., Bedard, C., Kim, D. J., Blumenfeld, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1163 · Cited by 205
Self-citationDevelopment of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Lack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies
Bien-Ly, N., Boswell, C. A., Jeet, S., Beach, T. G., Hoyte, K., Luk, W., Shihadeh, V., Ulufatu, S., Foreman, O., Lu, Y., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.09.036 · Cited by 198
Self-citationReceptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria
Haqqani, A. S., Bélanger, K., & Stanimirovic, D. B. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1360302 · Cited by 153
Barker, S. J., Thayer, M. B., Kim, C., Tatarakis, D., Simon, M. J., Dial, R., Nilewski, L., Wells, R. C., Zhou, Y., Afetian, M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi2245 · Cited by 142
Self-citationClark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123
Kucharz, K., Kristensen, K., Johnsen, K. B., Lund, M. A., Lønstrup, M., Moos, T., Andresen, T. L., & Lauritzen, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-24323-1 · Cited by 123
Tashima, T. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00854 · Cited by 120
Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia
Simon, M. J., Logan, T., DeVos, S. L., & Di Paolo, G. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.09.006 · Cited by 94
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Exploiting transferrin receptor for delivering drugs across the blood-brain barrier
Paterson, J., & Webster, C. I. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.07.009 · Cited by 87
Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.
Pizzo, M. E., Plowey, E. D., Khoury, N., Kwan, W., Abettan, J., DeVos, S. L., Discenza, C. B., Earr, T., Joy, D., Lye-Barthel, M., et al. (2025) · Science · doi:10.1126/science.ads3204 · Cited by 63
Self-citationGadkar, K., Yadav, D. B., Zuchero, J. Y., Couch, J. A., Kanodia, J., Kenrick, M. K., Atwal, J. K., Dennis, M. S., Prabhu, S., Watts, R. J., et al. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.009 · Cited by 52
“[4] have shown a strong dependence of the transcytosis process on the affinity of the antibody to TfR.”
BackgroundInfluentialSelf-citationRodrigues, R. O., Shin, S.-R., & Bañobre-López, M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02720-0 · Cited by 44
Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
Sumner, I. L., Edwards, R. A., Asuni, A. A., & Teeling, J. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00254 · Cited by 24
Liu, N., Liang, X., Yang, C., Hu, S., Luo, Q., & Luo, H. (2022) · Theranostics · doi:10.7150/thno.76574 · Cited by 21
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Metadata
- Authors
- Bien-Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., Luk, W., Lu, Y., Dennis, M. S., Weimer, R. M., Chung, I., & Watts, R. J.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-01-27
- Volume
- 211
- Issue
- 2
- Pages
- 233-244
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2100276489
- Cited by
- 353
- References
- 25
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.